专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20120082686A1 Neovascular-Targeted Immunoconjugates 有权
标题翻译：新血管内靶向免疫缀合物
公开(公告)号：US20120082686A1
公开(公告)日：2012-04-05
申请号：US13290497
申请日：2011-11-07
申请人： Alan GAREN , Zhiwei HU
发明人： Alan GAREN , Zhiwei HU
IPC分类号： A61K39/44 , A61P35/04 , A61P29/00 , A61P9/10 , A61P27/02 , A61P35/00
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/622 , C07K2317/732 , C07K2319/30
摘要： Immunoconjugates for treating diseases associated with neovascularization such as cancer, rheumatoid arthritis, the exudative form of macular degeneration, and atherosclerosis are described. The immunoconjugates typically consist of the Fc region of a human IgG1 immunoglobulin including the hinge, or other effector domain or domains that can elicit, when administered to a patient, a cytolytic immune response or cytotoxic effect against a targeted cell. The effector domain is conjugated to a targeting domain which comprises a factor VII mutant that binds with high affinity and specificity to tissue factor but does not initiate blood clotting such as factor VII having a substitution of alanine for lysine-341 or of alanine for serine-344.
摘要翻译：描述了用于治疗与新生血管形成相关疾病如癌症，类风湿性关节炎，渗出性黄斑变性和动脉粥样硬化的免疫缀合物。免疫缀合物通常由包含铰链的人IgG1免疫球蛋白的Fc区组成，或者当向患者施用时可以引发针对靶细胞的细胞溶解免疫应答或细胞毒性作用的其它效应结构域或结构域。效应结构域与靶向结构域结合，该靶向结构域包含以组合因子的高亲和性和特异性结合但不引发血液凝固的因子VII突变体，例如具有丙氨酸取代赖氨酸341或丙氨酸的丝氨酸 - 344。

2. 发明申请

US20110117114A1 Neovascular-Targeted Immunoconjugates 有权
标题翻译：新血管内靶向免疫缀合物
公开(公告)号：US20110117114A1
公开(公告)日：2011-05-19
申请号：US12977937
申请日：2010-12-23
申请人： Alan GAREN , Zhiwei HU
发明人： Alan GAREN , Zhiwei HU
IPC分类号： A61K39/395 , A61P29/00 , A61P35/00
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/622 , C07K2317/732 , C07K2319/30
摘要： Immunoconjugates for treating diseases associated with neovascularization such as cancer, rheumatoid arthritis, the exudative form of macular degeneration, and atherosclerosis are described. The immunoconjugates typically consist of the Fc region of a human IgG1 immunoglobulin including the hinge, or other effector domain or domains that can elicit, when administered to a patient, a cytolytic immune response or cytotoxic effect against a targeted cell. The effector domain is conjugated to a targeting domain which comprises a factor VII mutant that binds with high affinity and specificity to tissue factor but does not initiate blood clotting such as factor VII having a substitution of alanine for lysine-341 or of alanine for serine-344.
摘要翻译：描述了用于治疗与新生血管形成相关疾病如癌症，类风湿性关节炎，渗出性黄斑变性和动脉粥样硬化的免疫缀合物。免疫缀合物通常由人IgG1免疫球蛋白的Fc区组成，包括铰链，或当向患者施用时可以引发针对靶细胞的溶细胞免疫应答或细胞毒性作用的其他效应结构域或结构域。效应结构域与靶向结构域结合，该靶向结构域包含以组合因子的高亲和性和特异性结合但不引发血液凝固的因子VII突变体，例如具有丙氨酸取代赖氨酸341或丙氨酸的丝氨酸 - 344。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式